1010 related articles for article (PubMed ID: 17555947)
21. Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Li H; Luo J; Wang C; Xie S; Xu X; Wang X; Yu W; Gu N; Kane JM
Schizophr Res; 2014 Aug; 157(1-3):112-9. PubMed ID: 24994555
[TBL] [Abstract][Full Text] [Related]
22. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
23. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Kane JM; Meltzer HY; Carson WH; McQuade RD; Marcus RN; Sanchez R;
J Clin Psychiatry; 2007 Feb; 68(2):213-23. PubMed ID: 17335319
[TBL] [Abstract][Full Text] [Related]
24. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
[TBL] [Abstract][Full Text] [Related]
25. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials.
Ardizzone I; Nardecchia F; Marconi A; Carratelli TI; Ferrara M
Psychopharmacol Bull; 2010; 43(2):45-66. PubMed ID: 21052042
[TBL] [Abstract][Full Text] [Related]
26. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia.
Kane JM; Osuntokun O; Kryzhanovskaya LA; Xu W; Stauffer VL; Watson SB; Breier A
J Clin Psychiatry; 2009 Apr; 70(4):572-81. PubMed ID: 19323965
[TBL] [Abstract][Full Text] [Related]
27. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia.
Fleischhacker WW; McQuade RD; Marcus RN; Archibald D; Swanink R; Carson WH
Biol Psychiatry; 2009 Mar; 65(6):510-7. PubMed ID: 18986646
[TBL] [Abstract][Full Text] [Related]
28. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
29. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.
Kane JM; Sanchez R; Zhao J; Duca AR; Johnson BR; McQuade RD; Eramo A; Baker RA; Peters-Strickland T
J Med Econ; 2013 Jul; 16(7):917-25. PubMed ID: 23663091
[TBL] [Abstract][Full Text] [Related]
30. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
Newcomer JW; Meyer JM; Baker RA; Eudicone JM; Pikalov A; Vester-Blokland E; McQuade RD; Crandall DT; Carson WH; Marcus RN; L'italien G
Schizophr Res; 2008 Dec; 106(2-3):300-7. PubMed ID: 18973991
[TBL] [Abstract][Full Text] [Related]
31. Comparing the effectiveness of aripiprazole and quetiapine in schizophrenia and related psychoses: a naturalistic, retrospective chart review study.
Shajahan P; Keith S; Majjiga C; Murphy J; MacRae A; Bashir M; Taylor M
J Clin Psychiatry; 2009 May; 70(5):692-8. PubMed ID: 19284930
[TBL] [Abstract][Full Text] [Related]
32. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
Lu ML; Shen WW; Chen CH
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
[TBL] [Abstract][Full Text] [Related]
33. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
34. Aripiprazole for schizophrenia.
El-Sayeh HG; Morganti C
Cochrane Database Syst Rev; 2004; (2):CD004578. PubMed ID: 15106256
[TBL] [Abstract][Full Text] [Related]
35. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Kwon JS; Jang JH; Kang DH; Yoo SY; Kim YK; Cho SJ;
Psychiatry Clin Neurosci; 2009 Feb; 63(1):73-81. PubMed ID: 19154213
[TBL] [Abstract][Full Text] [Related]
36. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
[TBL] [Abstract][Full Text] [Related]
37. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).
Stroup TS; McEvoy JP; Ring KD; Hamer RH; LaVange LM; Swartz MS; Rosenheck RA; Perkins DO; Nussbaum AM; Lieberman JA;
Am J Psychiatry; 2011 Sep; 168(9):947-56. PubMed ID: 21768610
[TBL] [Abstract][Full Text] [Related]
38. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
[TBL] [Abstract][Full Text] [Related]
39. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
Pigott TA; Carson WH; Saha AR; Torbeyns AF; Stock EG; Ingenito GG;
J Clin Psychiatry; 2003 Sep; 64(9):1048-56. PubMed ID: 14628980
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Kane JM; Carson WH; Saha AR; McQuade RD; Ingenito GG; Zimbroff DL; Ali MW
J Clin Psychiatry; 2002 Sep; 63(9):763-71. PubMed ID: 12363115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]